Meda
Financials
Estimates*
EUR | 2015 |
---|---|
R&D budget | 23.0m |
Source: Dealroom estimates
Date | Investors | Amount | Round |
---|---|---|---|
- | N/A | - | |
$7.2b | Acquisition | ||
Total Funding | - |
Related Content
Recent News about Meda
EditViatris, formerly known as Mylan, is a global healthcare company dedicated to empowering people to live healthier lives at every stage. The company focuses on increasing access to high-quality medicines for patients worldwide, ensuring they receive the treatments they need when and where they need them. Viatris operates in the pharmaceutical industry, serving a diverse range of clients including healthcare providers, pharmacies, and patients. The company generates revenue through the development, manufacturing, and distribution of a broad portfolio of generic and branded medications. Viatris leverages its extensive global infrastructure and expertise to deliver cost-effective healthcare solutions, aiming to improve health outcomes and reduce healthcare costs. The company's business model is centered around innovation, quality, and accessibility, striving to meet the evolving needs of the global healthcare market.
Keywords: healthcare, pharmaceuticals, generic medicines, branded medications, global access, patient care, cost-effective, innovation, quality, infrastructure.